Question special

Optimizing patients with cirrhosis for elective / semi-elective procedures is challenging, especially in those with associated thrombocytopenia.

As a general question, what is your approach to optimizing patients with cirrhosis for surgery and other procedures?

As a more specific question, the FDA recently approved avatrombopag for patients with liver disease-associated severe thrombocytopenia undergoing elective procedures. Do you currently use or do you plan to use this agent in your practice? How does this compare to prophylactic platelets?